Kaleido Biosciences Inc
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of ulcerative colitis, psoriasis, atopic imm… Read more
Market Cap & Net Worth: Kaleido Biosciences Inc (KLDO)
Kaleido Biosciences Inc (PINK:KLDO) has a market capitalization of $4.26K ($4.26K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #46279 globally and #14441 in its home market, demonstrating a -90.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kaleido Biosciences Inc's stock price $0.00 by its total outstanding shares 42622559 (42.62 Million).
Kaleido Biosciences Inc Market Cap History: 2019 to 2025
Kaleido Biosciences Inc's market capitalization history from 2019 to 2025. Data shows change from $213.97 Million to $4.26K (-85.70% CAGR).
Kaleido Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kaleido Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
92.27x
Kaleido Biosciences Inc's market cap is 92.27 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $387.87 Million | $975.00K | -$79.80 Million | 397.81x | N/A |
| 2021 | $101.87 Million | $1.10 Million | -$90.29 Million | 92.27x | N/A |
Competitor Companies of KLDO by Market Capitalization
Companies near Kaleido Biosciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Kaleido Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Kaleido Biosciences Inc Historical Marketcap From 2019 to 2025
Between 2019 and today, Kaleido Biosciences Inc's market cap moved from $213.97 Million to $ 4.26K, with a yearly change of -85.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.26K | 0.00% |
| 2024 | $4.26K | -90.00% |
| 2022 | $42.62K | -99.96% |
| 2021 | $101.87 Million | -73.74% |
| 2020 | $387.87 Million | +81.27% |
| 2019 | $213.97 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kaleido Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.26K USD |
| MoneyControl | $4.26K USD |
| MarketWatch | $4.26K USD |
| marketcap.company | $4.26K USD |
| Reuters | $4.26K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.